JZJian Zhao

Jian Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Zhao has a total of 290 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Pei

    University of Chinese Academy of Sciences, Beijing, 100049, China

    21 shared publications
  • Gang Pei

    State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China

    20 shared publications
  • Ying Wang

    Cell and Gene Therapy Innovations Shanghai Clinical Research and Trial Center Shanghai China

    13 shared publications
  • Lan Ma

    School of Basic Medical Sciences, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

    8 shared publications
  • Jin Cui

    State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences Shanghai 200031 China

    6 shared publications
  • Xianglu Zeng

    ShanghaiTech Univ

    6 shared publications

Latest Publications

  • TREM2-Targeting peptide tracer for neuroinflammation PET imaging

    by Xiaoyu Zhang, Wenhao Liu, Na Guo, Xinyan Gao, Suyun Pu, Yabin Yang, Xiaochuan Zha, Kezhi Ding, Dai Shi, Jian Zhao, et al.

    Purpose Triggering receptor expressed on myeloid cells 2 (TREM2) has emerged as an important target in neurodegenerative diseases. However, noninvasive visualization of TREM2 expression in the central nervous system (CNS) remains challenging. This study aimed to develop and evaluate a novel peptide-based positron emission tomography (PET) tracer for imaging TREM2 in CNS. Methods A TREM2-targeting peptide was conjugated with DOTA and radiolabeled with gallium-68 to generate [68Ga]Ga-STZL730. Binding affinity, tracer stability, lipophilicity, and cellular uptake were evaluated. Dynamic PET imaging and blocking studies were performed in wild-type mice, TREM2 knockout mice, lipopolysaccharide (LPS)-induced neuroinflammation mice, and APP/PS1 Alzheimer’s disease (AD) model mice. Autoradiography and immunofluorescence staining were conducted to validate tracer specificity and target expression. Results [68Ga]Ga-STZL730 was synthesized with high radiochemical purity (> 99%) and demonstrated excellent stability in vitro. The tracer exhibited specific binding to TREM2 with an affinity (KD) of 274 nM. In vivo PET imaging demonstrated that [68Ga]Ga-STZL730 could cross the blood-brain barrier, displaying moderate and sustained brain uptake. Notably, at 20–35 min post-injection, compared to wild-type controls, brain uptake was significantly reduced in TREM2 knockout mice (41.6% lower), whereas it was markedly increased in both LPS-treated mice (113.8% higher) and AD mice (86.0% higher). Blocking studies in AD mice demonstrated the specific binding of [68Ga]Ga-STZL730. In vitro autoradiography and immunohistochemical analyses further confirmed that elevated PET signals corresponded to increased TREM2 expression, which was spatially localized to activated microglia in APP/PS1 mice brain sections. Conclusion [68Ga]Ga-STZL730 is a novel peptide-based PET tracer that enables specific, noninvasive imaging of TREM2 expression in the CNS. It provides a promising tool for investigating neuroinflammation and TREM2-associated pathology in neurodegenerative diseases.


  • Open Access

    CIAdex: Label‐Free Cell Identification and Aging Quantification Using Single‐Cell Infrared Spectral Fingerprints

    by Ying Wang, Yanfei Ding, Chengzhang He, Xiaojie Zhou, Junwu Tu, Yulei Deng, Jian Zhao

    Ensuring accurate cell identity and monitoring aging are critical for the safety and efficacy of cell therapies. Despite rapid iteration of methodology, current methods for characterizing cell products are often multi‐label dependent and lack sensitivity to subtle aging changes. Here we present Cell Identification and Aging Index (CIAdex), a machine‐learning framework that utilizes single‐cell Fourier‐transform infrared (FTIR) spectral fingerprints to achieve label‐free, precise cell identity verification and quantitative aging assessment. By extracting intrinsic FTIR spectral variables corresponding to distinct cellular biomolecular features and applying linear discriminant analysis and XGBoost algorithms, CIAdex enables distinction of lineage‐, donor‐, and batch‐specific cell populations, and generates a quantitative aging index (trPDL/trPN) that reflects cellular aging dynamics during culture expansion. Notably, trPDL/trPN quantitatively detects subtle age‐related shifts among different batches and drug‐induced senescence or rejuvenation effects, which are unmeasurable by conventional existing methods. Together, our work demonstrates that CIAdex offers a novel, robust, label‐free approach for simultaneous cell population identity verification and aging quantification, providing valuable metrics to enhance quality control and optimize efficacy in cell manufacturing and therapy development.

  • Open Access

    A human gut-BBB-brain microphysiological model for studying neurodegenerative diseases

    by Yu-Shan Deng, Wan-Peng Wang, Fei Wang, Guo-Ming Ma, Jian-Feng Lin, Chen-Xi Yan, Yi-Ling Zhou, Lu-Yao Wang, Xue-Qi Gong, Li Sun, et al.

    The gut-brain axis has emerged as a crucial factor in neurodegeneration, with growing evidence linking gut dysbiosis and metabolic dysfunction to Alzheimer’s disease (AD) progression. Unfortunately, the lack of human-relevant in vitro models limits our ability to effectively explore the mechanism of this axis. To address this gap, we have developed a human induced pluripotent stem cell (iPSC)-derived gut-blood-brain barrier (BBB)-brain microphysiological system that enables systematic investigation of gut-brain interaction in the context of AD under controlled conditions. Our findings reveal that the interaction between gut and brain organoids can promote the maturation of brain organoids, making them more similar to their physiological characteristics in vivo . Additionally, co-culture gut and brain organoids better recapitulates the pathological features of AD. We also discovered that gut organoids of AD can trigger neurodegenerative disease manifestations in healthy brain organoids. In summary, our microphysiological system provides a novel and versatile in vitro platform for studying the interaction between the gut and brain in neurodegenerative diseases.

  • Open Access

    Asc-2P Sustains Mitochondrial Glycolysis and Promotes Neural Progenitor Cell Activation via Metabotropic Glutamate Receptor 7

    by Jian Zhao, Ying Wang, Jing Fang, Ganlu Hu, Kailin Tang, Xianglu Zeng, Changzheng Wang, Yongcun Yu, Tao Zeng, Zhiwei Cao, et al.

    Human neural progenitor cells (hNPCs) have been reported to exist in various regions of the central nervous system (CNS) throughout the lifespan and to maintain homeostasis of the CNS. The endogenous NPC pools as well as their function decline during aging, neurodegeneration, or brain damage; therefore, supplementation with hNPCs or enhancement of the potency of endogenous NPCs could lead to potential treatments for these diseases. Here, we showed that 2-phospho-L-ascorbic acid (Asc-2P) promoted hNPC proliferation and differentiation by maintaining mitochondrial glycolysis under growth factor-lacking conditions. Upregulation of metabotropic glutamate receptor 7 (mGluR7) expression by Asc-2P treatment and retention of mGluR7 on the plasma membrane by the specific group III mGluR antagonist alpha-methylserine-O-phosphate (MSOP) promoted the formation of fibroblast growth factor receptor 1 (FGFR1) and mGluR7 complex on the cell membrane, thereby enhanced the phosphorylation and activation of cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), maintained mitochondrial glycolysis, thus enhanced hNPC proliferation and differentiation in vitro and in vivo. Furthermore, Asc-2P treatment alleviated pathogenesis and related cognitive decline in an Alzheimer’s disease mouse model. Taken together, our findings indicated that modulation of mGluR7 by Asc-2P and/or its antagonists could be promising pharmaceutical and therapeutic options against neurodegeneration and related diseases.

  • Open Access

    Asc-2P Sustains Mitochondrial Glycolysis and Promotes Neural Progenitor Cell Activation via Metabotropic Glutamate Receptor 7

    by Jian Zhao, Ying Wang, Jing Fang, Ganlu Hu, Kailin Tang, Xianglu Zeng, Changzheng Wang, Yongcun Yu, Tao Zeng, Zhiwei Cao, et al.

    Human neural progenitor cells (hNPCs) have been reported to exist in various regions of the central nervous system (CNS) throughout the lifespan and to maintain homeostasis of the CNS. The endogenous NPC pools as well as their function decline during aging, neurodegeneration, or brain damage; therefore, supplementation with hNPCs or enhancement of the potency of endogenous NPCs could lead to potential treatments for these diseases. Here, we showed that 2-phospho-L-ascorbic acid (Asc-2P) promoted hNPC proliferation and differentiation by maintaining mitochondrial glycolysis under growth factor-lacking conditions. Upregulation of metabotropic glutamate receptor 7 (mGluR7) expression by Asc-2P treatment and retention of mGluR7 on the plasma membrane by the specific group III mGluR antagonist alpha-methylserine-O-phosphate (MSOP) promoted the formation of fibroblast growth factor receptor 1 (FGFR1) and mGluR7 complex on the cell membrane, thereby enhanced the phosphorylation and activation of cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), maintained mitochondrial glycolysis, thus enhanced hNPC proliferation and differentiation in vitro and in vivo. Furthermore, Asc-2P treatment alleviated pathogenesis and related cognitive decline in an Alzheimer’s disease mouse model. Taken together, our findings indicated that modulation of mGluR7 by Asc-2P and/or its antagonists could be promising pharmaceutical and therapeutic options against neurodegeneration and related diseases.

  • Open Access

    Identification of Cerebrospinal Fluid Proteomic Signatures Associated with Intramedullary Surgery Outcome

    by Weihao Di, Wentao Gu, Xike Peng, Jiajun Shou, Yi Zhang, Shufei Ge, Jian Zhao, Shixin Gu, the Neurospine Group

    S: Importance: Neurological function recovery after intramedullary microsurgery is susceptible to various factors. Investigating alterations in cerebrospinal fluid (CSF) protein profiles associated with spinal function recovery could provide valuable insights into prognosis and the development of postoperative therapeutic approaches. Objective: The aim of this research was to identify CSF protein sets linked to recovery outcomes of intramedullary microsurgery. Design: This research is an observational cohort investigation that collected data from August 2020 to March 2023. Setting: The Neurospine group conducted this single-centered cohort research ( http://www.chictr.org.cn , registration ID: ChiCTR2300072704). Participants were followed up for 6 months or more. CSF samples were collected pre-and postoperatively. Perioperative treatments, neurological deficits, and rehabilitation therapies were recorded. Participants: The Neurospine group screened adult patients with intramedullary lesions scheduled for surgical intervention. The exclusion criteria included prior spinal surgery, neurological disorders, surgical complications, or relevant medications. Exposures: The patients underwent standard intramedullary microsurgical procedures, received medications, and underwent assessments. The CSF protein profiles were examined using tandem mass spectrometry. Main outcomes and measures: The evaluation of spinal function recovery involved various assessments and correlation analysis was performed. In addition, CSF protein features were identified and their clinical associations were assessed using least absolute shrinkage and selection operator (LASSO) regression modeling. Results: Of the 43 patients who completed follow-up assessments, 23 were women and 20 were men, with a mean age of 42.8±11.8 years. Histological diagnoses confirmed invasive lesions in 20 patients. Twenty-three patients demonstrated stable or improved spinal function, while 20 patients experienced deterioration during the 3rd and 6th month follow-ups. As indicated by the changes in EMS scales ( P = 0.02) and JOA scores ( P = 0.03), functional prognosis was associated with pathological characteristics. We developed four models using the CSF proteomics datasets of noninvasive and invasive patients. These LASSO regression models exhibited high accuracy in predicting the recovery rates of the corresponding groups ( P > 0.99). Conclusions and relevance: This research demonstrates that lesion sizes and pathological characteristics are significant factors influencing spinal function recovery. The LASSO regression models developed using identified CSF protein variables for invasive and noninvasive patients, respectively, offer novel methods for the prediction of prognosis and the development of therapeutic approaches.

  • Open Access

    Detection of Pathological Markers of Neurodegenerative Diseases following Microfluidic Direct Conversion of Patient Fibroblasts into Neurons

    by Cristiana Mollinari, Chiara De Dominicis, Leonardo Lupacchini, Luigi Sansone, Davide Caprini, Carlo Massimo Casciola, Ying Wang, Jian Zhao, Massimo Fini, Matteo Russo, et al.

    Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are clinically diagnosed using neuropsychological and cognitive tests, expensive neuroimaging-based approaches (MRI and PET) and invasive and time-consuming lumbar puncture for cerebrospinal fluid (CSF) sample collection to detect biomarkers. Thus, a rapid, simple and cost-effective approach to more easily access fluids and tissues is in great need. Here, we exploit the chemical direct reprogramming of patient skin fibroblasts into neurons (chemically induced neurons, ciNs) as a novel strategy for the rapid detection of different pathological markers of neurodegenerative diseases. We found that FAD fibroblasts have a reduced efficiency of reprogramming, and converted ciNs show a less complex neuronal network. In addition, ciNs from patients show misfolded protein accumulation and mitochondria ultrastructural abnormalities, biomarkers commonly associated with neurodegeneration. Moreover, for the first time, we show that microfluidic technology, in combination with chemical reprogramming, enables on-chip examination of disease pathological processes and may have important applications in diagnosis. In conclusion, ciNs on microfluidic devices represent a small-scale, non-invasive and cost-effective high-throughput tool for protein misfolding disease diagnosis and may be useful for new biomarker discovery, disease mechanism studies and design of personalised therapies.


  • Open Access

    SUN-129 The significance of β-catenin/Foxo in kidney transplantation

    by Y. Yang, P. Rao, J. Zhao, H. Yu, T. Chen, Q. Cao, Y. Wang, B. Nankivell, G. Zheng, D. Harris